Evidence map›Paper›PMID 37886135›Full record

ArticleCase reports in infectious diseases2023

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient.

Ferdinand Bigirimana, Sigi Van den Wijngaert, Christelle Fosso, Karolien Stoffels, Charlotte Martin, Evelyne Maillart, Philippe Clevenbergh

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ferdinand BigirimanaInfectious Diseases Department, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Sigi Van den WijngaertAids Reference Laboratory, Centre Hospitalier Universitaire St. Pierre, Brussels, Belgium.
Christelle FossoNephrology and Dialysis Department, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Karolien StoffelsAids Reference Laboratory, Centre Hospitalier Universitaire St. Pierre, Brussels, Belgium.
Charlotte MartinInfectious Diseases Department, University Hospital St Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Evelyne MaillartInfectious Diseases Department, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Philippe ClevenberghInfectious Diseases Department, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.ORCID https://orcid.org/0000-0002-0522-9686
Université Libre de Bruxelles · BECentre Hospitalier Universitaire de Saint-Pierre · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir looks promising in terms of safety and efficacy even in patients with end-stage renal disease awaiting renal transplant. Both drugs are first in class ARVs so that there is no cross resistance with previous drugs, maintaining their efficacy against MDR HIV.

Identifiers

PMID37886135
PMCPMC10599868
OpenAlexW4387763558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.